OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 26, 2022
Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.
Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.
May 24, 2022
A new initiative aims to speed the approval of and access to new drugs for young patients around the world, while limiting the number of children needed for testing in clinical trials.
Investment has been made into a new science hub at the University of Edinburgh for the development of treatments for lung infections and future pandemics.
May 16, 2022
Flexible and efficient methods are needed for biopharmaceutical manufacturing.
The latest manufacturing technologies are essential for helping pharmaceutical formulators meet up-and-coming trends in OSD treatments.
May 15, 2022
CGTs offer hope for the future of treatments, but the costly manufacturing, slow turnaround time, and need for supplies hinder progress.
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
May 11, 2022
The agency’s Center for Drug Evaluation and Research has launched the new program to increase development of treatment options for patients with rare diseases.
May 05, 2022
AstraZeneca has announced plans to open a new strategic R&D center in Cambridge, MA, which will also serve as Alexion’s headquarters.